Key Finding
Balloon dilation combined with acupuncture ranked among the top three interventions across multiple outcome measures for post-stroke cricopharyngeal achalasia, showing the best results for improving videofluoroscopic swallowing scores (SUCRA 92.0%) and reducing standardized swallowing assessment scores (SUCRA 80.0%).
Researchers analyzed 36 studies to find the best treatments for a swallowing problem called cricopharyngeal achalasia that can occur after stroke. This condition involves difficulty swallowing due to muscle dysfunction in the throat, affecting patients' ability to eat and drink safely.
The study compared 13 different treatment approaches, all involving a procedure called balloon dilation (stretching the throat muscle) combined with various additional therapies. Researchers looked at multiple measures including effectiveness rates, swallowing function scores, oral intake ability, and standardized swallowing assessments.
Key findings showed that combining balloon dilation with acupuncture ranked among the top three treatments across most outcome measures. Specifically, this combination showed the best results for improving videofluoroscopic swallowing scores and reducing swallowing assessment scores. For overall effectiveness rates, balloon dilation combined with repetitive transcranial magnetic stimulation (rTMS) ranked highest, while the combination with botulinum toxin injections showed best results for improving oral intake scores.
What this means for patients: If you've experienced swallowing difficulties after a stroke, acupuncture combined with balloon dilation may be a beneficial treatment option to discuss with your healthcare team. The research suggests this combination therapy can help improve swallowing function and safety. However, the researchers noted that more high-quality studies with larger patient groups are needed to confirm these findings, as the current studies had small sample sizes and some methodological limitations.
If considering acupuncture for post-stroke swallowing problems, seek a licensed acupuncturist with experience treating neurological conditions and work closely with your stroke rehabilitation team.
This network meta-analysis examined 36 RCTs comparing 13 interventions for post-stroke cricopharyngeal achalasia across four outcome measures: effective rate, VFSS scores, FOIS scores, and SSA scores. All interventions involved balloon dilation combined with adjunctive therapies.
Based on SUCRA rankings, balloon dilation combined with acupuncture demonstrated superior performance in VFSS improvement (92.0%) and SSA score reduction (80.0%), ranking third for effective rate (79.4%) and FOIS improvement (76.8%). Balloon dilation with rTMS showed highest effective rate (91.8%), while combination with BTX-A ranked best for FOIS scores (87.4%).
Clinical takeaway: Acupuncture as an adjunct to balloon dilation shows consistent benefit across multiple validated swallowing outcome measures for post-stroke cricopharyngeal achalasia, with particularly strong evidence for functional swallowing improvement. However, study limitations include small sample sizes, inadequate allocation concealment and blinding in some trials, and potential publication bias. Practitioners should consider acupuncture as part of multimodal treatment protocols while awaiting larger, methodologically rigorous trials to establish definitive treatment hierarchies.
Browse our directory of verified licensed practitioners near you.
Find a practitioner โ๐ Dysregulation of m7G RNA modifications, catalyzed by three major methyltransferase complexes in the CNS, is associated with the pathogenesis of multiple neurological diseases including Alzheimer's disease, ALS, epilepsy, glioblastoma, and ischemic stroke.
๐ Acupuncture significantly reduced thyroid antibodies (TPOAb and TGAb) and TSH levels in Hashimoto thyroiditis patients, though methodological limitations prevent reliable clinical recommendations pending higher-quality research.
๐ Liproxstatin-1 significantly reduced cerebral ischemia-reperfusion injury in rats by inhibiting ferroptosis through increasing neuroprotective factors GPX4 and FTH1 while decreasing ferroptosis markers NOX1, ACSL4, COX2, and TFR1.